Citalopram for Anxiety

Citalopram blocks the transporter that pulls serotonin back out of the synapse, so more of it stays in circulation between neurons. That much happens within days of your first tablet. The relief does not, and the gap between those two timelines is where most early quitting happens. It is also a once-daily tablet rather than something you take when anxiety spikes, which makes it a poor match if what you want is an in-the-moment tool.

One fact shapes the rest of this page. The FDA label approves citalopram for major depressive disorder in adults and lists no anxiety indication. Any prescription for anxiety is therefore off-label, which is legal and routine in psychiatry but means the dosing schedule and label warnings were built on depression studies. SSRIs remain the mainstay of drug treatment for generalized anxiety disorder, so the real question is usually which one, at what dose.

In a randomized trial of 475 adults with panic disorder, every citalopram dose beat placebo, 20 to 30 mg daily was generally most effective, and phobic symptom reduction kept increasing toward the end of treatment. That slow upward curve is the shape to expect from an SSRI in anxiety, and it is the opposite of what most anxiety treatments promise. Week four is not the ceiling of what you get, and your own response can vary widely from the trial average.

Compiled trial data suggest partial response in the first two to four weeks is common and is a good prognostic sign, while an adjustment period on the order of two months is often needed for the full clinical response. A useful way to run month one is to mark a date eight weeks out and stop auditing yourself daily. Daily checks catch side effects, which arrive first, and miss the drift in baseline worry, which arrives last.

It tends to fit when anxiety is chronic rather than situational, when cost is a real constraint, and when one tablet each morning suits you better than something as-needed. Duration is part of that fit. Continuing an antidepressant for at least six to 12 months is recommended to reduce relapse, and stopping earlier is associated with relapse rates as high as 50 percent, so this is a year-scale decision. It fits less well in situations that are unusually concrete for a psychiatric drug. The label restricts citalopram in congenital long QT syndrome, bradycardia, low potassium or magnesium, recent heart attack and uncompensated heart failure, and advises against combining it with other drugs that prolong the QTc interval. Whether any of that applies to you is a judgment a licensed clinician makes with your history in front of them.

The cleanest difference is regulatory. Escitalopram is FDA-approved for the acute treatment of generalized anxiety disorder in adults, starting at 10 mg once daily with an increase to 20 mg no sooner than a week later, while citalopram's own label covers major depressive disorder only. Chemically they are close: escitalopram is the single active enantiomer isolated from racemic citalopram. Regulatorily they are not close at all.

They also share a metabolic bottleneck that shows up in tolerability. Across 263 youth treated with escitalopram or citalopram, slower CYP2C19 metabolizers reported more adverse effects (p=0.015), more activation symptoms (p=0.029), and were likelier to stop treatment (p=0.007), while faster metabolizers responded more quickly (p=0.005). Genotype is rarely tested first, but it explains why two similar starting doses can feel nothing alike.

The label sets an initial dosage of 20 mg once daily, an increase to a maximum of 40 mg once daily at an interval of no less than one week, and states that doses above 40 mg are not recommended because of the risk of QT prolongation. This is what most distinguishes citalopram from its siblings, and the ceiling is there for a cardiac reason, not a potency one. Sertraline and escitalopram have headroom above their usual doses. Citalopram has none, so a partial response at 40 mg cannot be answered by going higher.

The ceiling drops further for several groups: 20 mg once daily is the maximum if you are over 60 years of age, have hepatic impairment, are a CYP2C19 poor metabolizer, or take cimetidine or another CYP2C19 inhibitor. The reason is measurable, since the mean QTc increase over placebo was 8.5 milliseconds at 20 mg and 18.5 milliseconds at 60 mg. For anxiety, expert consensus supports starting below the depression dose and titrating slowly, so a 10 mg start is common.

The first week is the part nobody prepares you for. In a prospective study of 301 adults starting an antidepressant, 7.0 percent developed jitteriness and anxiety syndrome, onset averaged 7.3 days, and the most frequent features were insomnia (42.9 percent), irritability (33.3 percent) and agitation (23.8 percent). A rough first week is a recognized pattern rather than proof the drug is wrong for you, and it is a reason to call your prescriber rather than tough it out alone.

Sexual side effects deserve blunt treatment because they go underreported. The label records ejaculation disorder at 6 percent versus 1 percent on placebo, impotence at 3 percent versus under 1 percent, and notes decreased libido and delayed or absent orgasm in females. A 2026 meta-analysis of 13 trials covering 5,941 adults found orgasm dysfunction about three times likelier on an SSRI than control (RR 3.28, 95% CI 2.33 to 4.60).

Every antidepressant carries the same boxed warning, and its numbers are specific rather than vague. In pooled placebo-controlled trials of roughly 77,000 adult and 4,500 pediatric participants, suicidal thoughts and behaviors were more frequent than placebo below age 25, at 14 additional cases per 1,000 treated under 18 and 5 additional per 1,000 at ages 18 to 24, against 1 fewer per 1,000 at ages 25 to 64. Under 25 that means closer monitoring early and after each dose change.

Citalopram is not a controlled substance, so online prescribing runs on ordinary state licensure rules rather than the tighter regime around stimulants and benzodiazepines. A video or asynchronous visit is usually enough to start it. What a careful intake screens for is narrower than you might expect: cardiac history, other QT-prolonging drugs, electrolyte monitoring where low potassium or magnesium is likely, and screening for bipolar disorder before any antidepressant is started.

Two things are worth volunteering if the form does not ask. Your age relative to 60, and any CYP2C19 inhibitor you take, because either moves your ceiling from 40 mg to 20 mg. Also say plainly that you are seeking treatment for anxiety, so the off-label framing sits in your chart rather than being assumed. None of this is medical advice, and suitability is decided by the clinician who evaluates you.

Medication and therapy are not competing options. SSRIs and SNRIs are described as the mainstay of pharmacotherapy for generalized anxiety disorder alongside cognitive behavioral therapy, and the practical argument for running both is timing rather than theory. Therapy gives you something to do during the weeks the tablet has not started working yet, and it leaves you with skills that do not stop when the prescription does. That matters given how often relapse follows an early stop.

Combination risk is the part to actually watch. The label warns that citalopram can precipitate serotonin syndrome, with risk raised alongside triptans, tramadol, lithium, buspirone and St. John's Wort, and separately that other QT-prolonging drugs compound the cardiac risk. Herbal and over-the-counter products count here, and they are the ones most often left off an intake form. Tell every prescriber you see, including a walk-in clinic writing you something unrelated, that you take citalopram.

The CMS National Average Drug Acquisition Cost file for 2026 prices a citalopram 20 mg tablet at about $0.029, a 10 mg tablet at about $0.024 and a 40 mg tablet at about $0.046, effective January 2026. Thirty 20 mg tablets is under a dollar at that benchmark. NADAC is what pharmacies pay rather than your counter price, but it sets the floor and explains why generic citalopram lands on discount lists so consistently.

So the drug is almost never the line item that matters.

Your monthly spend is the visit fee or membership, the dispensing markup, and the follow-ups. Price those carefully, because a drug with a fixed 40 mg ceiling and an eight-week response window needs one or two dose conversations before anyone knows whether it worked. A cheap first month with costly check-ins is the usual trap.

Continuity matters more here than for a one-and-done prescription, for two reasons already covered. Relief is judged at around eight weeks, and the dose has a hard ceiling that limits how much can be fixed by escalating.

A service that prescribes once and disappears leaves you no route to the dose conversation that decides whether this drug worked or simply was never given a fair run.

Ask about stopping before you start. Discontinuation symptoms typically emerge within two to four days of stopping or reducing, suggested tapers run from four weeks to six months with changes every two to four weeks, and citalopram sits in the intermediate-risk group. The label asks for gradual reduction rather than abrupt cessation wherever possible. A prescriber who can describe that in visit one is telling you something about month nine.